WO2012065019A3 - Combination comprising pyridopyrimidinone inhibitors of pi3k alpha - Google Patents

Combination comprising pyridopyrimidinone inhibitors of pi3k alpha Download PDF

Info

Publication number
WO2012065019A3
WO2012065019A3 PCT/US2011/060293 US2011060293W WO2012065019A3 WO 2012065019 A3 WO2012065019 A3 WO 2012065019A3 US 2011060293 W US2011060293 W US 2011060293W WO 2012065019 A3 WO2012065019 A3 WO 2012065019A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
pi3k alpha
pyridopyrimidinone
inhibitors
pyridopyrimidinone inhibitors
Prior art date
Application number
PCT/US2011/060293
Other languages
French (fr)
Other versions
WO2012065019A2 (en
Inventor
Dana T. Aftab
Arthur Decillis
Original Assignee
Exelixis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.
Publication of WO2012065019A2 publication Critical patent/WO2012065019A2/en
Publication of WO2012065019A3 publication Critical patent/WO2012065019A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to methods, combinations, and formulations of a compound of Formula I.
PCT/US2011/060293 2010-11-12 2011-11-11 Pyridopyrimidinone inhibitors of p13k alpha WO2012065019A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41335610P 2010-11-12 2010-11-12
US61/413,356 2010-11-12

Publications (2)

Publication Number Publication Date
WO2012065019A2 WO2012065019A2 (en) 2012-05-18
WO2012065019A3 true WO2012065019A3 (en) 2012-10-04

Family

ID=45044729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/060293 WO2012065019A2 (en) 2010-11-12 2011-11-11 Pyridopyrimidinone inhibitors of p13k alpha

Country Status (1)

Country Link
WO (1) WO2012065019A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149308A1 (en) * 2011-04-29 2012-11-01 Exelixis, Inc. Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
CN110269856A (en) 2010-03-30 2019-09-24 维颂公司 Inhibitor of the polysubstituted aromatic compounds as fibrin ferment
TW201306842A (en) * 2011-06-15 2013-02-16 Exelixis Inc Combination therapies for treating hematologic malignancies using pyridopyrimidinone inhibitors of PI3K/MTOR with bendamustine and/or rituximab
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2014058947A1 (en) * 2012-10-12 2014-04-17 Sanofi Compositions and methods for treating cancer using pi3k inhibitor and anti-cd19 maytansinoid immunoconjugate
TW201521792A (en) * 2013-03-05 2015-06-16 Sanofi Sa Tablet formulation of a PI3K[alpha] inhibitor
US9951025B2 (en) 2013-03-15 2018-04-24 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
CA3051327A1 (en) * 2013-03-15 2014-09-18 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI657085B (en) 2013-10-04 2019-04-21 英菲尼提製藥股份有限公司 Heterocyclic compounds and uses thereof
ES2913486T3 (en) 2014-03-19 2022-06-02 Infinity Pharmaceuticals Inc Heterocyclic Compounds for Use in the Treatment of PI3K-gamma Mediated Disorders
KR20170048410A (en) 2014-09-17 2017-05-08 베르선 코포레이션 Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2018506563A (en) 2015-02-27 2018-03-08 ヴァーセオン コーポレイション Substituted pyrazole compounds as serine protease inhibitors
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
MA45280B1 (en) 2016-03-02 2021-08-31 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use thereof
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2022234998A1 (en) * 2021-03-08 2023-10-12 Jinan University Pyridopyrimidine compounds and applications thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044698A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
WO2008127678A1 (en) * 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
KR101492795B1 (en) 2005-10-07 2015-02-13 엑셀리시스, 인코포레이티드 PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
SI2139484T1 (en) 2007-04-10 2013-10-30 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044698A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
WO2008127678A1 (en) * 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, pages 103a, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2001 (2001-11-16), HU WEI ET AL: "PI3K/Akt as a potential therapeutic target in AML", XP000266172, Database accession no. PREV200200129866 *
ERCUMENT CENGIZ ET AL: "Overcoming drug resistance in hormone and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination", MOLECULAR BIOLOGY REPORTS ; AN INTERNATIONAL JOURNAL ON MOLECULAR AND CELLULAR BIOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 37, no. 3, 14 March 2009 (2009-03-14), pages 1269 - 1277, XP019772929, ISSN: 1573-4978 *
FDA: "Summary of Color Additives for Use in the United States in Foods, Drugs, Cosmetics, and Medical Devices", 22 March 2007 (2007-03-22), XP002675594, Retrieved from the Internet <URL:http://www.fda.gov/ForIndustry/ColorAdditives/ColorAdditiveInventories/ucm115641.htm> [retrieved on 20120302] *
KILIC A ET AL: "Efficacy of Signal Pathway Inhibitors Alone and in Combination With Cisplatin Varies Between Human Non-Small Cell Lung Cancer Lines", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 154, no. 1, 1 June 2009 (2009-06-01), pages 9 - 12, XP026097116, ISSN: 0022-4804, [retrieved on 20080620], DOI: 10.1016/J.JSS.2008.05.022 *

Also Published As

Publication number Publication date
WO2012065019A2 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
WO2012065057A3 (en) Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2013003298A3 (en) Inhibitors of pde10
IL235944A0 (en) Β-lactamase inhibitor compounds, compositions comprising same, methods of producing same and uses thereof
IL222484A0 (en) Arginase inhibitor compounds, compositions comprising the same and uses thereof
WO2012158843A3 (en) Kinase inhibitors
WO2012159051A3 (en) Chemically modified graphene
IL235155B (en) Arginase inhibitor compounds, compositions comprising same and uses thereof
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EP2582664A4 (en) Phenylthioacetate compounds, compositions and methods of use
WO2012058211A3 (en) Quinazoline derivatives, compositions, and uses related thereto
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
CA2873723A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
IL221906B (en) Pde10 inhibitor compounds, compositions comprising the same and uses thereof
EP2566477A4 (en) Amino-quinolines as kinase inhibitors
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
WO2011143772A9 (en) Inhibitors of hiv replication
IL223865A0 (en) Calcium salts of dihydrooroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof
PL3070091T3 (en) Benzodioxole derivatives as phosphodiesterase inhibitors
IT1403156B1 (en) PHOSPHATIDYLINOSITOL 3-CHINASE INHIBITORS, RELATED COMPOSITIONS AND USES.
WO2011123524A3 (en) Macrolide inhibitors of mtor
WO2012154879A3 (en) Autophagy inhibitors
EP2544542A4 (en) Analgesic compounds, compositions, and uses thereof
WO2010059639A3 (en) Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11788286

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11788286

Country of ref document: EP

Kind code of ref document: A2